Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China

BACKGROUND: Programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors are increasingly used in China, but no real-world data are available about the immune-related adverse events (irAEs). This real-world retrospective study aimed to assess the safety and effectiveness of PD-1/PD...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiaoling, Nie, Jun, Dai, Ling, Hu, Weiheng, Zhang, Jie, Han, Jindi, Ma, Xiangjuan, Tian, Guangming, Han, Sen, Wu, Di, Wang, Yang, Long, Jieran, Zhang, Ziran, Fang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973369/
https://www.ncbi.nlm.nih.gov/pubmed/33747922
http://dx.doi.org/10.3389/fonc.2021.607531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973369/
https://www.ncbi.nlm.nih.gov/pubmed/33747922
http://dx.doi.org/10.3389/fonc.2021.607531

Ejemplares similares